logo-loader

AtaiBeckley reports encouraging Phase 2a data for EMP-01 in social anxiety

AtaiBeckley Inc. CEO Dr Srinivas Rao joined Steve Darling from Proactive to discuss topline results from the company’s exploratory, double-blind, placebo-controlled Phase 2a trial evaluating EMP-01 in adults with Social Anxiety Disorder (SAD).The first-in-patient study met its primary safety...

on 03/03/2026